Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Insight Molecular Diagnostics (IMDX) Asset Writedowns and Impairment (2020 - 2024)

Historic Asset Writedowns and Impairment for Insight Molecular Diagnostics (IMDX) over the last 3 years, with Q4 2024 value amounting to $36.9 million.

  • Insight Molecular Diagnostics' Asset Writedowns and Impairment rose 92260000.0% to $36.9 million in Q4 2024 from the same period last year, while for Dec 2024 it was $38.7 million, marking a year-over-year increase of 47284.3%. This contributed to the annual value of $41.9 million for FY2024, which is 52009.77% up from last year.
  • Per Insight Molecular Diagnostics' latest filing, its Asset Writedowns and Impairment stood at $36.9 million for Q4 2024, which was up 92260000.0% from -$4000.0 recorded in Q4 2023.
  • Insight Molecular Diagnostics' 5-year Asset Writedowns and Impairment high stood at $36.9 million for Q4 2024, and its period low was -$334000.0 during Q3 2020.
  • Its 3-year average for Asset Writedowns and Impairment is $7.3 million, with a median of $1.1 million in 2020.
  • Examining YoY changes over the last 5 years, Insight Molecular Diagnostics' Asset Writedowns and Impairment showed a top increase of 92260000.0% in 2024 and a maximum decrease of 92260000.0% in 2024.
  • Insight Molecular Diagnostics' Asset Writedowns and Impairment (Quarter) stood at $334000.0 in 2020, then tumbled by 101.2% to -$4000.0 in 2023, then skyrocketed by 922600.0% to $36.9 million in 2024.
  • Its Asset Writedowns and Impairment stands at $36.9 million for Q4 2024, versus -$4000.0 for Q4 2023 and $1.8 million for Q3 2023.